Aker BioMarine Collaborate with Université de Sherbrooke Department of Medicine for Alzheimer’s Disease

 Aker BioMarine Collaborate with Université de Sherbrooke Department of Medicine for Alzheimer’s Disease

Aker BioMarine Collaborate with Université de Sherbrooke Department of Medicine for Alzheimer’s Disease

Shots:

  • The alliance will investigate the effectiveness of LPC-bound EPA/DHA in preventing cognitive decline linked to AD. Aker BioMarine will supply the research team with its krill-based LPC EPA/DHA product (Lysoveta)
  • The team will evaluate the link between genetic variations in lipid metabolism & transport of EPA/DHA across the BBB using knock-in mice for human E4 (hAPOE4) or E3 (hAPOE3) genetic variants
  • Aker BioMarine launches Lysoveta based on LPC-bound EPA/DHA from krill and is effective in increasing the concentration of DHA in the brain and improving cognition. The company plans to launch a product for human health in 2022

Click here ­to­ read full press release/ article | Ref: Aker BioMarine | Image: Aker BioMarine

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post